Egg allergy Egg allergy, epicutaneous immunotherapy
Conditions
Interventions
Patients with hen's egg allergy are randomized to receive A: high concentrated ovomucoid-containing hydrophilic gel patch, B: low concentrated ovomucoid-containing hydrophilic gel patch or C: placebo
immunotherapy
Sponsors
Iwai Fumiko
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1 Immediate-type of hen's egg allergy 2 specific IgE to egg white at 3.5 UA/mL or more 3 Participants who have threshold of egg protein cumulative dose of 150mg or less
Exclusion criteria
Exclusion criteria: 1 Participants with severe symptoms in oral food challenge for hen's egg allergy 2 Participants who have had only gastrointestinal symptoms as allergic symptoms 3 Poorly controlled participants with bronchial asthma and/or atopic dermatitis 4 Participants receiving immunotherapy for other food allergens during this trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of participants who pass oral food challenge to 150mg of egg protein at 24 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1 Proportion of participants who pass oral food challenge to 500 mg of egg protein at 24 or 48 weeks 2 Proportion of participants who pass oral food challenge to 150 mg of egg protein at 48 weeks 3 Adverse event 4 Changes in immunological markers | — |
Contacts
Public ContactFumiko Iwai
National Hospital Organization Mie National Hospital
Outcome results
None listed